Journal article
RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting
J Healer, JK Thompson, KL Mackwell, CD Browne, BA Seager, A Ngo, KN Lowes, SE Silk, D Pulido, LDW King, JM Christen, AR Noe, V Kotraiah, PJ Masendycz, R Rajagopalan, L Lucas, MM Stanford, L Soisson, C Diggs, R Miller Show all
Frontiers in Cellular and Infection Microbiology | FRONTIERS MEDIA SA | Published : 2022
Abstract
Background: RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, designated RCR, is essential for entry into human erythrocytes. RH5 has advanced to human clinical trials, and the impact on parasite growth in the blood was encouraging but modest. This study assessed the potential of a protein-in-adjuvant blood stage malaria vaccine based on a combination of RH5, Ripr and CyRPA to provide improved neutralizing activity against P. falciparum in vitro. Methods: Mice were immunized with the indivi..
View full abstractGrants
Awarded by United States Agency for International Development